Emergence, virology, immune response after SARS‐CoV‐2 infection, and role of immunopathology behind vaccination

Abstract

In mid-January 2020, the WHO received information from the International Commission of Health about
an outbreak of disease in the capital of Hubei province, Wuhan, in Central China. There was no evidence
of human transmission or infection among health-care workers at that stage. Initially, the cases identified
visiting the Wuhan live and seafood market prompted a suspicion that might be the source of the pandemic.
Stumbling of more than 200 vaccines started with preclinical progress, but only approximately 40 vaccines
entered clinical trials where some were not approved for human trials. This review addresses the genome
sequence, immunopathology induced by virus, and vaccine.